Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives

Angelika Wagner, Birgit Weinberger, Angelika Wagner, Birgit Weinberger

Abstract

Infectious diseases are a major cause for morbidity and mortality in the older population. Demographic changes will lead to increasing numbers of older persons over the next decades. Prevention of infections becomes increasingly important to ensure healthy aging for the individual, and to alleviate the socio-economic burden for societies. Undoubtedly, vaccines are the most efficient health care measure to prevent infections. Age-associated changes of the immune system are responsible for decreased immunogenicity and clinical efficacy of most currently used vaccines in older age. Efficacy of standard influenza vaccines is only 30-50% in the older population. Several approaches, such as higher antigen dose, use of MF59 as adjuvant and intradermal administration have been implemented in order to specifically target the aged immune system. The use of a 23-valent polysaccharide vaccine against Streptococcus pneumoniae has been amended by a 13-valent conjugated pneumococcal vaccine originally developed for young children several years ago to overcome at least some of the limitations of the T cell-independent polysaccharide antigens, but still is only approximately 50% protective against pneumonia. A live-attenuated vaccine against herpes zoster, which has been available for several years, demonstrated efficacy of 51% against herpes zoster and 67% against post-herpetic neuralgia. Protection was lower in the very old and decreased several years after vaccination. Recently, a recombinant vaccine containing the viral glycoprotein gE and the novel adjuvant AS01B has been licensed. Phase III studies demonstrated efficacy against herpes zoster of approx. 90% even in the oldest age groups after administration of two doses and many countries now recommend the preferential use of this vaccine. There are still many infectious diseases causing substantial morbidity in the older population, for which no vaccines are available so far. Extensive research is ongoing to develop vaccines against novel targets with several vaccine candidates already being clinically tested, which have the potential to substantially reduce health care costs and to save many lives. In addition to the development of novel and improved vaccines, which specifically target the aged immune system, it is also important to improve uptake of the existing vaccines in order to protect the vulnerable, older population.

Keywords: Streptococcus pneumoniae; adjuvant; elderly; herpes zoster; high-dose; immunosenescence; influenza; vaccine.

Copyright © 2020 Wagner and Weinberger.

Figures

FIGURE 1
FIGURE 1
Challenges and opportunities of vaccination in old age. The older population is at increased risk for infections and severe course of disease, while immune responses to infections, and vaccines are impaired. Several factors, such as immunosenescence, underlying chronic diseases and medications as well as the history of previous infections and vaccinations influence the risk for the individual and lead to heterogeneity within this age group. Current vaccines for the older population are an efficient measure for preventing infectious diseases, but there is still much room for improvement. For optimal protection of the older population improved vaccines need to be developed. This includes the use of adjuvants, vaccines against additional pathogens, universal vaccines targeting variable pathogens, induction of cellular immune responses, mucosal delivery, and the prevention of immunosenescence. Of equal importance are strategies to improve vaccination. Optimal vaccine schedules and improved vaccination coverage rates are essential to maximize the benefit we draw from vaccination. Public awareness and knowledge as well as easy access to vaccination are crucial to reach these goals.

References

    1. United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects 2019: Highlights. (ST/ESA/SER.A/423). New York, NY: United Nations; (2019).
    1. Janssens JP. Pneumonia in the elderly (geriatric) population. Curr Opin Pulm Med. (2005) 11:226–30.
    1. Herpes Zoster and Functional Decline Consortium. Functional decline and herpes zoster in older people: an interplay of multiple factors. Aging Clin Exp Res. (2015) 27:757–65. 10.1007/s40520-015-0450-0
    1. Drew W, Wilson DV, Sapey E. Inflammation and neutrophil immunosenescence in health and disease: targeted treatments to improve clinical outcomes in the elderly. Exp Gerontol. (2018) 105:70–7. 10.1016/j.exger.2017.12.020
    1. Agrawal A, Agrawal S, Gupta S. Role of dendritic cells in inflammation and loss of tolerance in the elderly. Front Immunol. (2017) 8:1–8. 10.3389/fimmu.2017.00896
    1. Lorenzo EC, Bartley JM, Haynes L. The impact of aging on CD4+ T cell responses to influenza infection. Biogerontology. (2018) 19:437–66. 10.1007/s10522-018-9754-8
    1. Goronzy JJ, Fang F, Cavanagh MM, Qi Q, Weyand CM. Naive T cell maintenance and function in human aging. J Immunol. (2015) 194:4073–80. 10.4049/jimmunol.1500046
    1. Jergoviæ M, Smithey MJ, Nikolich-Žugich J. Intrinsic and extrinsic contributors to defective CD8+ T cell responses with aging. Exp Gerontol. (2018) 105:140–5. 10.1016/j.exger.2018.01.011
    1. Gustafson CE, Weyand CM, Goronzy JJ. T follicular helper cell development and functionality in immune ageing. Clin Sci. (2018) 132:1925–35. 10.1042/CS20171157
    1. Frasca D, Blomberg BB. B cell function and influenza vaccine responses in healthy aging and disease. Curr Opin Immunol. (2014) 29:112–8. 10.1016/j.coi.2014.05.008
    1. Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and human vaccine immune responses. Immun Ageing. (2019) 16:1–16. 10.1186/s12979-019-0164-9
    1. Pinti M, Appay V, Campisi J, Frasca D, Fülöp T, Sauce D, et al. Aging of the immune system: focus on inflammation and vaccination. Eur J Immunol. (2016) 46:2286–301. 10.1002/eji.201546178
    1. Kwetkat A, Heppner HJ. Comorbidities in the elderly and their possible influence on vaccine response. In: Weinberger B. editor. Vaccines for Older Adults: Current Practices and Future Opportunities. Interdiscp Top Gerontol Geriatr. Basel: Karger; (2020). p. 73–85. 10.1159/000504489
    1. Frasca D, Blomberg BB. The impact of obesity and metabolic syndrome on vaccination success. In: Weinberger B. editor. Vaccines for Older Adults: Current Practices and Future Opportunities. Interdiscp Top Gerontol Geriatr. Basel: Karger; (2020). p. 86–97. 10.1159/000504440
    1. Nath KD, Burel JG, Shankar V, Pritchard AL, Towers M, Looke D, et al. Clinical factors associated with the humoral immune response to influenza vaccination in chronic obstructive pulmonary disease. Int J COPD. (2013) 9:51–6. 10.2147/COPD.S53590
    1. Vardeny O, Moran JJ, Johnson MR, Sweitzer NK. Antibody titers to influenza vaccine wane in patients with heart failure. J Card Fail. (2009) 15:S33.
    1. Suaya JA, Jiang Q, Scott DA, Gruber WC, Webber C, Schmoele-Thoma B, et al. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults. Vaccine. (2018) 36:1477–83. 10.1016/j.vaccine.2018.01.049
    1. Weltevrede M, Eilers R, de Melker HE, van Baarle D. Cytomegalovirus persistence and T-cell immunosenescence in people aged fifty and older: a systematic review. Exp Gerontol. (2016) 77:87–95. 10.1016/j.exger.2016.02.005
    1. Goodier MR, Jonjiæ S, Riley EM, Juraniæ Lisniæ VC. MV. and natural killer cells: shaping the response to vaccination. Eur J Immunol. (2018) 48:50–65. 10.1002/eji.201646762
    1. Wikby A, Ferguson F, Forsey R, Thompson J, Strindhall J, Löfgren S, et al. An immune risk phenotype, cognitive impairment, and survival in very late life: Impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol Ser A Biol Sci Med Sci. (2005) 60:556–65. 10.1093/gerona/60.5.556
    1. Du Y, Zhang G, Liu Z. Human cytomegalovirus infection and coronary heart disease: a systematic review. Virol J. (2018) 15:31. 10.1186/s12985-018-0937-3
    1. Wang S, Wang T, Zhang W, Liu X, Wang X, Wang H, et al. Cohort study on maternal cytomegalovirus seroprevalence and prevalence and clinical manifestations of congenital infection in China. Med (U S). (2017) 96:1–6. 10.1097/MD.0000000000006007
    1. Frasca D, Blomberg BB. Aging, cytomegalovirus (CMV) and influenza vaccine responses. Hum Vaccines Immunother. (2016) 12:682–90. 10.1080/21645515.2015.1105413
    1. Trzonkowski P, Myśliwska J, Szmit E, Wi?ckiewicz J, Łukaszuk K, Brydak LB, et al. Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination-An impact of immunosenescence. Vaccine. (2003) 21:3826–36. 10.1016/S0264-410X(03)00309-8
    1. Weinberger B, Keller M, Grubeck-Loebenstein B. Long-term maintenance of diphtheria-specific antibodies after booster vaccination is hampered by latent infection with Cytomegalovirus. Immun Ageing. (2017) 14:16. 10.1186/s12979-017-0099-y
    1. van den Berg SPH, Warmink K, Borghans JAM, Knol MJ, van Baarle D. Effect of latent cytomegalovirus infection on the antibody response to influenza vaccination: a systematic review and meta-analysis. Med Microbiol Immunol. (2019) 208:305–21. 10.1007/s00430-019-00602-z
    1. Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. (2018) 391:1285–300. 10.1016/S0140-6736(17)33293-2
    1. Dugan HL, Henry C, Wilson PC. Aging and influenza vaccine-induced immunity. Cell Immunol. (2020) 348:103998. 10.1016/j.cellimm.2019.103998
    1. Govaert TME, Thijs CTMCN, Masurel N, Sprenger MJW, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals a randomized double-blind placebo-controlled trial from the departments of general practice. JAMA. (1994) 272:1661–5.
    1. Kwong JC, Campitelli MA, Gubbay JB, Peci A, Winter AL, Olsha R, et al. Vaccine effectiveness against laboratory-confirmed influenza hospitalizations among elderly adults during the 2010-2011 season. Clin Infect Dis. (2013) 57:820–7. 10.1093/cid/cit404
    1. Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. (2018) 2:CD001269. 10.1002/14651858.CD001269.pub6
    1. Beran J, Vesikari T, Wertzova V, Karvonen A, Honegr K, Lindblad N, et al. Efficacy of inactivated split−virus influenza vaccine against culture−confirmed influenza in healthy adults: a prospective. Randomized Placebo Controlled Trial J Infect Dis. (2009) 200:1861–9. 10.1086/648406
    1. Lewnard JA, Cobey S. Immune history and influenza vaccine effectiveness. Vaccines. (2018) 6:28. 10.3390/vaccines6020028
    1. Kon TC, Onu A, Berbecila L, Lupulescu E, Ghiorgisor A, Kersten GF, et al. Influenza vaccine manufacturing: Effect of inactivation, splitting and site of manufacturing. Comparison of influenza vaccine production processes. PLoS One. (2016) 11:e0150700. 10.1371/journal.pone.0150700
    1. Beyer WEP, Palache AM, Osterhaus ADME. Comparison of Serology and Reactogenicity between Influenza Subunit Vaccines and Whole Virus or Split Vaccines A Review and Meta-Analysis of the Literature. Clin Drug Investig. (1998) 15:1–12.
    1. Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, et al. Safety and immunogenicity of AS03 B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ. (2010) 340:1292. 10.1136/bmj.c2649
    1. Tisa V, Barberis I, Faccio V, Paganino C, Trucchi C, Martini M, et al. Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden. J Prev Med Hyg. (2016) 57:E28–33.
    1. Carlock MA, Ingram JG, Clutter EF, Cecil NC, Ramgopal M, Zimmerman RK, et al. Impact of age and pre-existing immunity on the induction of human antibody responses against influenza B viruses. Hum Vaccines Immunother. (2019) 15:2030–43. 10.1080/21645515.2019.1642056
    1. Kissling E, Nunes B, Robertson C, Valenciano M, Reuss A, Larrauri A, et al. I-MOVE multicentre case–control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? Eurosurveillance. (2016) 21:30201. 10.2807/1560-7917.ES.2016.21.16.30201
    1. Andrew MK, Bowles SK, Pawelec G, Haynes L, Kuchel GA, McNeil SA, et al. Influenza vaccination in older adults: recent innovations and practical applications. Drugs and Aging. (2019) 36:29–37. 10.1007/s40266-018-0597-4
    1. BMASGK. Impfplan Österreich. Vienna: BMASGK; (2020).
    1. Krammer F. The human antibody response to influenza A virus infection and vaccination. Nat Rev Immunol. (2019) 19:383–97. 10.1038/s41577-019-0143-6
    1. Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G. Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert Rev Vaccines. (2017) 16:723–36. 10.1080/14760584.2017.1334554
    1. Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004–2005 season to the 2006–2007 season. J Infect Dis. (2009) 199:159–67. 10.1086/595861
    1. Sano K, Ainai A, Suzuki T, Hasegawa H. The road to a more effective influenza vaccine: up to date studies and future prospects. Vaccine. (2017) 35:5388–95. 10.1016/j.vaccine.2017.08.034
    1. McElhaney JE, Andrew MK, McNeil SA. Estimating influenza vaccine effectiveness: Evolution of methods to better understand effects of confounding in older adults. Vaccine. (2017) 35:6269–74. 10.1016/j.vaccine.2017.09.084
    1. Ward BJ, Pillet S, Charland N, Trepanier S, Couillard J, Landry N. The establishment of surrogates and correlates of protection: useful tools for the licensure of effective influenza vaccines? Hum Vaccines Immunother. (2018) 14:647–56. 10.1080/21645515.2017.1413518
    1. Frasca D, Diaz A, Romero M, Blomberg BB. The generation of memory B cells is maintained, but the antibody response is not, in the elderly after repeated influenza immunizations. Vaccine. (2016) 34:2834–40. 10.1016/j.vaccine.2016.04.023
    1. Shahid Z, Kleppinger A, Gentleman B, Falsey AR, McElhaney JE. Clinical and immunologic predictors of influenza illness among vaccinated older adults. Vaccine. (2010) 28:6145–51. 10.1016/j.vaccine.2010.07.036
    1. Merani S, Kuchel GA, Kleppinger A, McElhaney JE. Influenza vaccine-mediated protection in older adults: impact of influenza infection, cytomegalovirus serostatus and vaccine dosage. Exp Gerontol. (2018) 107:116–25. 10.1016/j.exger.2017.09.015
    1. Sautto GA, Kirchenbaum GA, Ross TM. Towards a universal influenza vaccine: Different approaches for one goal. Virol J. (2018) 15:17. 10.1186/s12985-017-0918-y
    1. DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. (2014) 371:635–45. 10.1056/NEJMoa1315727
    1. Wilkinson K, Wei Y, Szwajcer A, Rabbani R, Zarychanski R, Abou-Setta AM, et al. Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis. Vaccine. (2017) 35:2775–80. 10.1016/j.vaccine.2017.03.092
    1. Lee JKH, Lam GKL, Shin T, Kim J, Krishnan A, Greenberg DP, et al. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expert Rev Vaccines. (2018) 17:435–43. 10.1080/14760584.2018.1471989
    1. Co MDT, Orphin L, Cruz J, Pazoles P, Green KM, Potts J, et al. In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses. Vaccine. (2009) 27:319–27. 10.1016/j.vaccine.2008.09.092
    1. Talbot HK, Nian H, Zhu Y, Chen Q, Williams JV, Griffin MR. Clinical effectiveness of split-virion versus subunit trivalent influenza vaccines in older adults. Clin Infect Dis. (2015) 60:1170–5. 10.1093/cid/civ019
    1. Kumar A, McElhaney JE, Walrond L, Cyr TD, Merani S, Kollmann TR, et al. Cellular immune responses of older adults to four influenza vaccines: Results of a randomized, controlled comparison. Hum Vaccines Immunother. (2017) 13:2048–57. 10.1080/21645515.2017.1337615
    1. Dunkle LM, Izikson R, Patriarca P, Goldenthal KL, Muse D, Callahan J, et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N Engl J Med. (2017) 376:2427–36. 10.1056/NEJMoa1608862
    1. Cowling BJ, Perera RAPM, Valkenburg SA, Leung NHL, Iuliano AD, Tam YH, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis. (2019) ciz1034. 10.1093/cid/ciz1034
    1. Engelke L, Winter G, Hook S, Engert J. Recent insights into cutaneous immunization: how to vaccinate via the skin. Vaccine. (2015) 33:4663–74. 10.1016/j.vaccine.2015.05.012
    1. Marra F, Young F, Richardson K, Marra CAA. Meta-analysis of intradermal versus intramuscular influenza vaccines: immunogenicity and adverse events. Influenza Other Respi Viruses. (2013) 7:584–603. 10.1111/irv.12000
    1. Nunzi E, Iorio AM, Camilloni B. A 21-winter seasons retrospective study of antibody response after influenza vaccination in elderly and very elderly institutionalized subject. Hum Vaccines Immunother. (2017) 13:2659–68. 10.1080/21645515.2017.1373226
    1. Pileggi C, Mascaro V, Bianco A, Nobile CGA, Pavia M. Immunogenicity and safety of intradermal influenza vaccine in the elderly: a meta-analysis of randomized controlled trials. Drugs Aging. (2015) 32:857–69. 10.1007/s40266-015-0303-8
    1. Hung IFN, Yuen KY. Immunogenicity, safety and tolerability of intradermal influenza vaccines. Hum Vaccines Immunother. (2018) 14:565–70. 10.1080/21645515.2017.1328332
    1. Young F, Marra F. A systematic review of intradermal influenza vaccines. Vaccine. (2011) 29:8788–801. 10.1016/j.vaccine.2011.09.077
    1. Scheifele DW, McNeil SA, Ward BJ, Dionne M, Cooper C, Coleman B, et al. Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison. Hum Vaccines Immunother. (2013) 9:2460–73. 10.4161/hv.25580
    1. Beyer WEP, Nauta JJP, Palache AM, Giezeman KM, Osterhaus ADME. Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis. Vaccine. (2011) 29:5785–92. 10.1016/j.vaccine.2011.05.040
    1. Moser C, Müller M, Kaeser MD, Weydemann U, Amacker M. Influenza virosomes as vaccine adjuvant and carrier system. Expert Rev Vaccines. (2013) 12:779–91. 10.1586/14760584.2013.811195
    1. Gasparini R, Lai P. Utility of virosomal adjuvated influenza vaccines: a review of the literature. J Prev Med Hyg. (2010) 51:1–6.
    1. Conne P, Gauthey L, Vernet P, Althaus B, Que JU, Finkelg B, et al. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine. (1997) 15:1675–9.
    1. Domnich A, Arata L, Amicizia D, Puig-Barberà J, Gasparini R, Panatto D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis. Vaccine. (2017) 35:513–20. 10.1016/j.vaccine.2016.12.011
    1. Weinberger B. Adjuvant strategies to improve vaccination of the elderly population. Curr Opin Pharmacol. (2018) 41:34–41. 10.1016/j.coph.2018.03.014
    1. Camilloni B, Basileo M, Valente S, Nunzi E, Iorio AM. Immunogenicity of intramuscular MF59- Adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: a literature review. Hum Vaccines Immunother. (2015) 11:553–63. 10.1080/21645515.2015.1011562
    1. Nicolay U, Heijnen E, Nacci P, Patriarca PA, Leav B. Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults =65 years of age: Meta-analysis of cumulative clinical experience. Int J Infect Dis. (2019) 85:S1–9. 10.1016/j.ijid.2019.03.026
    1. Orsi A, Ansaldi F, De Florentiis D, Ceravolo A, Parodi V, Canepa P, et al. Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines. Hum Vaccines Immunother. (2013) 9:582–90. 10.4161/hv.23239
    1. Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, Malzone C, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA. (2009) 106:3877–82. 10.1073/pnas.0813390106
    1. Pebody RG, Whitaker H, Ellis J, Andrews N, Marques DFP, Cottrell S, et al. End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom in 2018/19. Vaccine. (2020) 38:489–97. 10.1016/j.vaccine.2019.10.071
    1. Pebody R, Whitaker H, Zhao H, Andrews N, Ellis J, Donati M, et al. Protection provided by influenza vaccine against influenza-related hospitalisation in =65 year olds: early experience of introduction of a newly licensed adjuvanted vaccine in England in 2018/19. Vaccine. (2020) 38:173–9. 10.1016/j.vaccine.2019.10.032
    1. Weinberg A, Lazar AA, Zerbe GO, Hayward AR, Chan ISF, Vessey R, et al. Influence of age and nature of primary infection on varicella−zoster virus–specific cell−mediated immune responses. J Infect Dis. (2010) 201:1024–30. 10.1086/651199
    1. Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. (2013) 81:928–30. 10.1212/wnl.0b013e3182a3516e
    1. Johnson RW, Rice ASC. Postherpetic neuralgia. N Engl J Med. (2014) 371:1526–33. 10.1056/NEJMcp1403062
    1. Opstelten W, McElhaney J, Weinberger B, Oaklander AL, Johnson RW. The impact of varicella zoster virus: chronic pain. J Clin Virol. (2010) 48:S8–13. 10.1016/S1386-6532(10)70003-2
    1. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpse zoster and postherpetic neuralgia in older adults. N Engl J Med. (2005) 352:2271–84.
    1. Schmader KE, Levin MJ, Gnann JW, McNeil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. (2012) 54:922–8. 10.1093/cid/cir970
    1. Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. (2015) 60:900–9. 10.1093/cid/ciu918
    1. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, et al. Varicella−zoster virus–specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. (2008) 197:825–35. 10.1086/528696
    1. Weinberg A, Popmihajlov Z, Schmader KE, Johnson MJ, Caldas Y, Salazar AT, et al. Persistence of varicella-zoster virus cell-mediated immunity after the administration of a second dose of live herpes zoster vaccine. J Infect Dis. (2019) 219:335–8. 10.1093/infdis/jiy514
    1. Garçon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines. (2011) 10:10.1586/erv.11.29. 10.1586/erv.11.29
    1. Del Giudice G, Rappuoli R, Didierlaurent AM. Correlates of adjuvanticity: a review on adjuvants in licensed vaccines. Semin Immunol. (2018) 39:14–21. 10.1016/j.smim.2018.05.001
    1. Detienne S, Welsby I, Collignon C, Wouters S, Coccia M, Delhaye S, et al. Central role of CD169+ lymph node resident macrophages in the adjuvanticity of the QS-21 component of AS01. Sci Rep. (2016) 6:39475. 10.1038/srep39475
    1. Welsby I, Detienne S, N’Kuli F, Thomas S, Wouters S, Bechtold V, et al. Lysosome-dependent activation of human dendritic cells by the vaccine adjuvant QS-21. Front Immunol. (2017) 7:663. 10.3389/fimmu.2016.00663
    1. Lacaille-Dubois MA. Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review. Phytomedicine. (2019) 60:152905. 10.1016/j.phymed.2019.152905
    1. Didierlaurent AM, Laupèze B, Di Pasquale A, Hergli N, Collignon C, Garçon N. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines. (2017) 16:55–63. 10.1080/14760584.2016.1213632
    1. Vandepapelière P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine. (2008) 26:1375–86. 10.1016/j.vaccine.2007.12.038
    1. Dendouga N, Fochesato M, Lockman L, Mossman S, Giannini SL. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine. (2012) 30:3126–35. 10.1016/j.vaccine.2012.01.088
    1. Coccia M, Collignon C, Hervé C, Chalon A, Welsby I, Detienne S, et al. Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity. NPJ Vaccines. (2017) 2:25. 10.1038/s41541-017-0027-3
    1. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. (2016) 375:1019–32. 10.1056/NEJMoa1603800
    1. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. (2015) 372:2087–96. 10.1056/NEJMoa1501184
    1. Cunningham AL, Heineman TC, Lal H, Godeaux O, Chlibek R, Hwang SJ, et al. Immune responses to a recombinant glycoprotein e herpes zoster vaccine in adults aged 50 years or older. J Infect Dis. (2018) 217:1750–60. 10.1093/infdis/jiy095
    1. Chlibek R, Bayas JM, Collins H, De La Pinta MLR, Ledent E, Mols JF, et al. Safety and immunogenicity of an ASO1 -adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults =50 years of age. J Infect Dis. (2013) 208:1953–61. 10.1093/infdis/jit365
    1. Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JAR, Richardus JH, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. (2014) 32:1745–53. 10.1016/j.vaccine.2014.01.019
    1. Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapelière P, Vassilev V, Ledent E, et al. Phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis. (2012) 206:1280–90. 10.1093/infdis/jis497
    1. Schwarz TF, Volpe S, Catteau G, Chlibek R, David MP, Richardus JH, et al. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccines Immunother. (2018) 14:1370–7. 10.1080/21645515.2018.1442162
    1. Heineman TC, Cunningham A, Levin M. Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine. Curr Opin Immunol. (2019) 59:42–8. 10.1016/j.coi.2019.02.009
    1. Vink P, Ramon Torrell JM, Sanchez Fructuoso A, Kim S-J, Kim S, Zaltzman J, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase III, randomized clinical trial. Clin Infect Dis. (2019) 70:181–90. 10.1093/cid/ciz177
    1. Berkowitz EM, Moyle G, Stellbrink HJ, Schürmann D, Kegg S, Stoll M, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. (2015) 211:1279–87. 10.1093/infdis/jiu606
    1. Bastidas A, De La Serna J, El Idrissi M, Oostvogels L, Quittet P, López-Jiménez J, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA J Am Med Assoc. (2019) 322:123–33. 10.1001/jama.2019.9053
    1. Curran D, Matthews S, Rowley SD, Young JAH, Bastidas A, Anagnostopoulos A, et al. Recombinant zoster vaccine significantly reduces the impact on quality of life caused by herpes zoster in adult autologous hematopoietic stem cell transplant recipients: a randomized placebo-controlled trial (ZOE-HSCT). Biol Blood Marrow Transplant. (2019) 25:2474–81. 10.1016/j.bbmt.2019.07.036
    1. Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. (2019) 19:988–1000. 10.1016/S1473-3099(19)30163-X
    1. Vink P. Immunogenicity and safety of a candidate subunit adjuvanted herpes zoster vaccine in adults with solid tumors vaccinated before or during immunosuppressive chemotherapy treatment: a phase II/III, randomized clinical trial. Open Forum Inf Dis. (2017) 4:S417–8.
    1. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol. (1995) 33:2759–62.
    1. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. (2018) 18:318–27. 10.1016/S1473-3099(17)30753-3
    1. Drijkoningen JJC, Rohde GGU. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. (2014) 20:45–51. 10.1111/1469-0691.12461
    1. Kim L, McGee L, Tomczyk S, Beall B. Biological and epidemiological features of antibiotic-resistant Streptococcus pneumoniae in pre- and post-conjugate vaccine eras: a United States perspective. Clin Microbiol Rev. (2016) 29:525–52. 10.1128/CMR.00058-15
    1. Schroeder MR, Stephens DS. Macrolide resistance in Streptococcus pneumoniae. Front Cell Infect Microbiol. (2016) 6:1–9. 10.3389/fcimb.2016.00098
    1. Cherazard R, Epstein M, Doan T, Salim T, Bharti S, Smith M. Antimicrobial resistant Streptococcus pneumoniae: prevalence, mechanisms, and clinical implications. Am J Ther. (2017) 24:e361–9. 10.1097/MJT.0000000000000551
    1. Cornick JE, Bentley SD. Streptococcus pneumoniae?: the evolution of antimicrobial resistance to beta-lactams, fluoroquinolones and macrolides. Microbes Infect. (2012) 14:573–83. 10.1016/j.micinf.2012.01.012
    1. Adler H, Ferreira DM, Gordon SB, Rylance J. Pneumococcal capsular polysaccharide immunity in the elderly. Clin Vaccine Immunol. (2017) 24:1–18.
    1. Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. (2018) 16:355–67. 10.1038/s41579-018-0001-8
    1. De Steenhuijsen Piters WAA, Huijskens EGW, Wyllie AL, Biesbroek G, Van Den Bergh MR, Veenhoven RH, et al. Dysbiosis of upper respiratory tract microbiota in elderly pneumonia patients. ISME J. (2016) 10:97–108. 10.1038/ismej.2015.99
    1. Hirst RA, Kadioglu A, O’Callaghan C, Andrew PW. The role of pneumolysin in pneumococcal pneumonia and meningitis. Clin Exp Immunol. (2004) 138:195–201. 10.1111/j.1365-2249.2004.02611.x
    1. Pettigrew MM, Marks LR, Kong Y, Gent JF, Roche-Hakansson H, Hakansson AP. Dynamic changes in the Streptococcus pneumoniae transcriptome during transition from biofilm formation to invasive disease upon influenza A virus infection. Infect Immun. (2014) 82:4607–19. 10.1128/IAI.02225-14
    1. Klein EY, Monteforte B, Gupta A, Jiang W, May L, Hsieh YH, et al. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respi Viruses. (2016) 10:394–403. 10.1111/irv.12398
    1. Henckaerts I, Goldblatt D, Ashton L, Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol. (2006) 13:356–60. 10.1128/CVI.13.3.356-360.2006
    1. Song JY, Moseley MA, Burton RL, Nahm MH. Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother. (2013) 19:412–25.
    1. MacIntyre CR, Ridda I, Trent MJ, McIntyre P. Persistence of immunity to conjugate and polysaccharide pneumococcal vaccines in frail, hospitalised older adults in long-term follow up. Vaccine. (2019) 37:5016–24. 10.1016/j.vaccine.2019.07.005
    1. Park S, Nahm MH. Older adults have a low capacity to opsonize pneumococci due to low igm antibody response to pneumococcal vaccinations. Infect Immun. (2011) 79:314–20. 10.1128/IAI.00768-10
    1. Lee H, Nahm MH, Burton R, Kim KH. Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin Vaccine Immunol. (2009) 16:376–81. 10.1128/CVI.00344-08
    1. Oishi T, Ishiwada N, Matsubara K, Nishi J, Chang B, Tamura K, et al. Low opsonic activity to the infecting serotype in pediatric patients with invasive pneumococcal disease. Vaccine. (2013) 31:845–9. 10.1016/j.vaccine.2012.11.010
    1. Burton RL, Nahm MH. Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20. Clin Vaccine Immunol. (2012) 19:835–41. 10.1128/CVI.00086-12
    1. Romero−Steiner S, Musher DM, Cetron MS, Pais LB, Groover JE, Carlone GM. Reduction in functional antibody activity against streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis. (1999) 29:281–8. 10.1086/520200
    1. Lue C, Tarkowski A, Mestecky J. Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases of both serum and secretory anti-pneumococcal antibodies. J Immunol. (1988) 140:3793–800.
    1. Roche AM, Richard AL, Rahkola JT, Janoff EN, Weiser JN. Antibody blocks acquisition of bacterial colonization through agglutination. Mucosal Immunol. (2015) 8:176–85. 10.1038/mi.2014.55
    1. Kelly DF, Snape MD, Cutterbuck EA, Green S, Snowden C, Diggle L, et al. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. Blood. (2006) 108:2642–7. 10.1182/blood-2006-01-009282
    1. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection agaisnt invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol. (2009) 426:422–6.
    1. Weller S, Reynaud CA, Weill JC. Vaccination against encapsulated bacteria in humans: paradoxes. Trends Immunol. (2005) 26:85–9. 10.1016/j.it.2004.11.004
    1. Smith DH, Peter G, Ingram DL, Harding AL, Anderson P. Responses of children immunized with the capsular polysaccharde of hemophilus influenzae type b. Pediatrics. (1973) 52:637–44.
    1. van den Biggelaar AHJ, Pomat WS. Immunization of newborns with bacterial conjugate vaccines. Vaccine. (2013) 31:2525–30. 10.1016/j.vaccine.2012.06.019
    1. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. (2010) 201:32–41. 10.1086/648593
    1. Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis. (2018) 18:441–51. 10.1016/S1473-3099(18)30052-5
    1. Wu YCB, Kipling D, Dunn-Walters DK. Age-related changes in human peripheral blood IGH repertoire following vaccination. Front Immunol. (2012) 3:1–12. 10.3389/fimmu.2012.00193
    1. Kolibab K, Smithson SL, Shriner AK, Khuder S, Romero-Steiner S, Carlone GM, et al. Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults. I Antibody concentrations, avidity and functional activity. Immun Ageing. (2005) 2:1–9. 10.1186/1742-4933-2-10
    1. de Roux A, Schmöele−Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis. (2008) 46:1015–23. 10.1086/529142
    1. Ridda I, MacIntyre CR, Lindley R, Gao Z, Sullivan JS, Yuan FF, et al. Immunological responses to pneumococcal vaccine in frail older people. Vaccine. (2009) 27:1628–36. 10.1016/j.vaccine.2008.11.098
    1. MacIntyre CR, Ridda I, Gao Z, Moa AM, McIntyre PB, Sullivan JS, et al. A randomized clinical trial of the immunogenicity of 7-valent pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, hospitalized elderly. PLoS One. (2014) 9:e94578. 10.1371/journal.pone.0094578
    1. Miernyk KM, Butler JC, Bulkow LR, Singleton RJ, Hennessy TW, Dentinger CM, et al. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55–70 years of age. Clin Infect Dis. (2009) 49:241–8. 10.1086/599824
    1. Musher DM, Manoff SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle−aged and older adults. J Infect Dis. (2010) 201:516–24. 10.1086/649839
    1. Jackson LA, Neuzil KM, Nahm MH, Whitney CG, Yu O, Nelson JC, et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. (2007) 25:4029–37. 10.1016/j.vaccine.2007.02.062
    1. Vadlamudi NK, Parhar K, Altre Malana KL, Kang A, Marra F. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis. Vaccine. (2019) 37:1021–9. 10.1016/j.vaccine.2019.01.014
    1. Marra F, Vadlamudi NK. Efficacy and safety of the pneumococcal conjugate-13 valent vaccine in adults. Aging Dis. (2019) 10:404–18. 10.14336/AD.2018.0512
    1. Falkenhorst G, Remschmidt C, Harder T, Hummers-Pradier E, Wichmann O, Bogdan C. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (ppv23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One. (2017) 12:1–18. 10.1371/journal.pone.0169368
    1. Diao W, Shen N, Yu P, Liu B, He B. Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: a systematic review and meta-analysis of randomized trials. Vaccine. (2016) 34:1496–503. 10.1016/j.vaccine.2016.02.023
    1. Kraicer-Melamed H, O’Donnell S, Quach C. The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: a systematic review and meta-analysis. Vaccine. (2016) 34:1540–50. 10.1016/j.vaccine.2016.06.045
    1. Schiffner-Rohe J, Witt A, Hemmerling J, Von Eiff C, Leverkus FW. Efficacy of PPV23 in preventing pneumococcal pneumonia in adults at increased risk-A systematic review and meta-analysis. PLoS One. (2016) 11:1–21. 10.1371/journal.pone.0146338
    1. Moberley S, Holden J, Tatham T, Andrews R. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. (2013) 1:CD000422.
    1. Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. (2015) 372:1114–25. 10.1056/NEJMoa1408544
    1. Richmond P, Kaczmarski E, Borrow R, Findlow J, Clark S, McCann R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis. (2000) 181:761–4. 10.1086/315284
    1. Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged =65 years: updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. (2019) 68:1069–75. 10.15585/mmwr.mm6846a5
    1. Kaplan A, Aresnault P, Aw B, Brown V, Fox G, Grossman R, et al. Vaccine strategies for prevention of community-acquired pneumonia in Canada. Candadian Fam Physician. (2019) 65:625–33.
    1. Vila-Córcoles A, Ochoa-Gondar O, de Diego C, Satué E, Vila-Rovira A, Aragón M. Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia. Spain, 2017. Eurosurveillance. (2019) 24:1–9. 10.2807/1560-7917.ES.2019.24.29.1800446
    1. Norris T, Vahratian A, Cohen RA.Vaccination Coverage Among Adults Aged 65 and Over: United States, 2015. NCHS Data Brief, No 281. Hyattsville, MD: National Center for Health Statistics; (2017). p. 1–8.
    1. Black CL, Williams WW, Warnock R, Pilishvili T, Kim D, Kelman JA. Pneumococcal vaccination among medicare beneficiaries occurring after the advisory committee on immunization practices recommendation for routine use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults. Morb Mortal Wkly Rep. (2017) 66:728–33. 10.15585/mmwr.mm6627a4
    1. Nachbagauer R, Krammer F. Universal influenza virus vaccines and therapeutic antibodies. Clin Microbiol Infect. (2017) 23:222–8. 10.1016/j.cmi.2017.02.009
    1. Kumar A, Sundebo Meldgaard T, Bertholet S. Novel platforms for the development of a universal inuenza vaccine. Front Immunol. (2018) 9:600 10.3389/mmu.2018.00600
    1. Impagliazzo A, Milder F, Kuipers H, Wagner MV, Zhu XB, Hoffman RM, et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science. (2015) 349:1301–6. 10.1126/science.aac7263
    1. Van Der Lubbe JEM, Verspuij JWA, Huizingh J, Schmit-Tillemans SPR, Tolboom JTBM, Dekking LEHA, et al. Mini-HA is superior to full length hemagglutinin immunization in inducing stem-specific antibodies and protection against group 1 influenza virus challenges in mice. Front Immunol. (2018) 9:2350. 10.3389/fimmu.2018.02350
    1. Eisenstein MA. Shot for all seasons. Nature. (2019) 573:S50–2. 10.1038/d41586-019-02751-w
    1. Stacey HL, Rosen J, Peterson JT, Williams-Diaz A, Gakhar V, Sterling TM, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Hum Vaccines Immunother. (2019) 15:530–9. 10.1080/21645515.2018.1532249
    1. Lu YJ, Yadav P, Clements JD, Forte S, Srivastava A, Thompson CM, et al. Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin Vaccine Immunol. (2010) 17:1005–12. 10.1128/CVI.00036-10
    1. Lu YJ, Leite L, Gonçalves VM, Dias W, de O, Liberman C, et al. GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine. (2010) 28:7468–75. 10.1016/j.vaccine.2010.09.031
    1. Campos IB, Herd M, Moffitt KL, Lu YJ, Darrieux M, Malley R, et al. 17A and complement contribute to killing of pneumococci following immunization with a pneumococcal whole cell vaccine. Vaccine. (2017) 35:1306–15. 10.1016/j.vaccine.2017.01.030
    1. Campo JJ, Le TQ, Pablo JV, Hung C, Teng AA, Tettelin H, et al. Panproteome-wide analysis of antibody responses to whole cell pneumococcal vaccination. eLife. (2018) 7:e37015. 10.7554/eLife.37015
    1. Keech CA, Morrison R, Anderson P, Tate A, Flores J, Goldblatt D, et al. Trial to evaluate the safety and immunogenicity of inactivated Streptococcus pneumoniae whole-cell vaccine in adults. Pediatr Infect Dis J. (2019): 10.1097/INF.0000000000002567 [Epub ahead of print].
    1. Chan WY, Entwisle C, Ercoli G, Ramos-Sevillano E, McIlgorm A, Cecchini P, et al. A novel, multiple-antigen pneumococcal vaccine protects against lethal Streptococcus pneumoniae challenge. Infect Immun. (2019) 87:1–18. 10.1128/IAI.00846-18
    1. Ferreira DM, Neill DR, Bangert M, Gritzfeld JF, Green N, Wright AKA, et al. Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults. Am J Respir Crit Care Med. (2013) 187:855–64. 10.1164/rccm.201212-2277OC
    1. Simell B, Lahdenkari M, Reunanen A, Käyhty H, Väkeväinen M. Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins. Clin Vaccine Immunol. (2008) 15:1391–7. 10.1128/CVI.00110-08
    1. Pichichero ME, Khan MN, Xu Q. Next generation protein based Streptococcus pneumoniae vaccines. Hum Vaccines Immunother. (2016) 12:194–205. 10.1080/21645515.2015.1052198
    1. Pichichero ME. Pneumococcal whole-cell and protein-based vaccines: changing the paradigm. Expert Rev Vaccines. (2017) 16:1181–90. 10.1080/14760584.2017.1393335
    1. Lagousi T, Basdeki P, Routsias J, Spoulou V. Novel protein-based pneumococcal vaccines: assessing the use of distinct protein fragments instead of full-length proteins as vaccine antigens. Vaccines. (2019) 7:1–18. 10.3390/vaccines7010009
    1. Asahi-Ozaki Y, Yoshikawa T, Iwakura Y, Suzuki Y, Tamura SI, Kurata T, et al. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus. J Med Virol. (2004) 74:328–35. 10.1002/jmv.20173
    1. Terauchi Y, Sano K, Ainai A, Saito S, Taga Y, Ogawa-Goto K, et al. IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration. Hum Vaccines Immunother. (2018) 14:1351–61. 10.1080/21645515.2018.1438791
    1. Valli E, Harriett A, Nowakowska M, Baudier R, Provosty W, McSween Z, et al. LTA1 is a safe, intranasal enterotoxin-based adjuvant that improves vaccine protection against influenza in young, old and B-cell-depleted (μMT) mice. Sci Rep. (2019) 9:15128. 10.1038/s41598-019-51356-w
    1. Tregoning JS, Russell RF, Kinnear E. Adjuvanted influenza vaccines. Hum Vaccines Immunother. (2018) 14:550–64. 10.1080/21645515.2017.1415684
    1. Geeraedts F, Goutagny N, Hornung V, Severa M, De Haan A, Pool J, et al. Superior immunogenicity of inactivated whole virus h5n1 influenza vaccine is primarily controlled by toll-like receptor signalling. PLoS Pathog. (2008) 4:e1000138. 10.1371/journal.ppat.1000138
    1. Ainai A, Suzuki T, Tamura SI, Hasegawa H. Intranasal administration of whole inactivated influenza virus vaccine as a promising influenza vaccine candidate. Viral Immunol. (2017) 30:451–62. 10.1089/vim.2017.0022
    1. Bhide Y, Dong W, Gribonika I, Voshart D, Meijerhof T, De Vries-Idema J, et al. Cross-protective potential and protection-relevant immune mechanisms of whole inactivated influenza virus vaccines are determined by adjuvants and route of immunization. Front Immunol. (2019) 10:646. 10.3389/fimmu.2019.00646
    1. Chason KD, Jaspers I, Parker J, Sellers S, Brighton LE, Hunsucker SA, et al. Age-associated changes in the respiratory epithelial response to influenza infection. J Gerontol Ser A Biol Sci Med Sci. (2018) 73:1643–50. 10.1093/gerona/gly126
    1. Wright AKA, Bangert M, Gritzfeld JF, Ferreira DM, Jambo KC, Wright AD, et al. Experimental Human Pneumococcal carriage augments IL-17A-dependent T-cell defence of the lung. PLoS Pathog. (2013) 9:e1003274. 10.1371/journal.ppat.1003274
    1. Wright AKA, Ferreira DM, Gritzfeld JF, Wright AD, Armitage K, Jambo KC, et al. Human nasal challenge with streptococcus pneumoniae is immunising in the absence of carriage. PLoS Pathog. (2012) 8:e1002622. 10.1371/journal.ppat.1002622
    1. Menzel M, Muellinger B, Weber N, Haeussinger K, Ziegler-Heitbrock L. Inhalative vaccination with pneumococcal polysaccharide in healthy volunteers. Vaccine. (2005) 23:5113–9. 10.1016/j.vaccine.2005.05.040
    1. Meyer P, Menzel M, Muellinger B, Weber N, Haeussinger K, Ziegler-Heitbrock L. Inhalative vaccination with pneumococcal polysaccharide in patients with chronic obstructive pulmonary disease. Vaccine. (2006) 24:5832–8. 10.1016/j.vaccine.2006.05.002
    1. Gordon SB, Malamba R, Mthunthama N, Jarman ER, Jambo K, Jere K, et al. Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses. Vaccine. (2008) 26:5400–6. 10.1016/j.vaccine.2008.07.082
    1. Frey SE, Lottenbach KR, Hill H, Blevins TP, Yu Y, Zhang Y, et al. A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA. Vaccine. (2013) 31:4874–80. 10.1016/j.vaccine.2013.07.049
    1. Gonçalves VM, Kaneko K, Soloranzo C, MacLoughlin R, Saleem I, Miyaji EN. Progress in mucosal immunization for protection against pneumococcal pneumonia. Expert Rev Vaccines. (2019) 18:781–92. 10.1080/14760584.2019.1643719
    1. Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D. Vaccination in the elderly: the challenge of immune changes with aging. Semin Immunol. (2018) 40:83–94. 10.1016/j.smim.2018.10.010
    1. Nicholson KG, Abrams KR, Batham S, Clark TW, Hoschler K, Shen Lim W, et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03 A-adjuvanted 2009 infl uenza A (H1N1) vaccines: a randomised, multicentre, age-stratifi ed, head-to-head trial. Lancet Infect Dis. (2011) 11:91–101. 10.1016/S1473
    1. Shi S, Zhu H, Xia X, Liang Z, Ma X, Sun B. Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity. Vaccine. (2019) 37:3167–78. 10.1016/j.vaccine.2019.04.055
    1. Moris P, Van Der Most R, Leroux-Roels I, Clement F, Dramé M, Hanon E, et al. H5N1 influenza vaccine formulated with AS03 A induces strong Cross-reactive and polyfunctional CD4 T-Cell responses. J Clin Immunol. (2011) 31:443–54. 10.1007/s10875-010-9490-6
    1. Van Doorn E, Liu H, Huckriede A, Hak E. Safety and tolerability evaluation of the use of Montanide ISATM51 as vaccine adjuvant: A systematic review. Hum Vaccines Immunother. (2016) 12:159–69. 10.1080/21645515.2015.1071455
    1. Reimer JM, Karlsson KH, Lövgren-Bengtsson K, Magnusson SE, Fuentes A, Stertman L. Matrix-mTM adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PLoS One. (2012) 7:e41451. 10.1371/journal.pone.0041451
    1. Hung IFN, Zhang AJ, To KKW, Chan JFW, Li CC, ShunZhu H, et al. Immunogenicity of intradermal trivalent influenza vaccine with topical imiquimod: a double blind randomized controlled trial. Clin Infect Dis. (2014) 59:1246–55. 10.1093/cid/ciu582
    1. Taylor DN, Treanor JJ, Strout C, Johnson C, Fitzgerald T, Kavita U, et al. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125. STF2.HA1 SI). Vaccine. (2011) 29:4897–902. 10.1016/j.vaccine.2011.05.001
    1. Pauksens K, Nilsson AC, Caubet M, Pascal TG, Van Belle P, Poolman JT, et al. Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02Vin elderly adults. Clin Vaccine Immunol. (2014) 21:651–60. 10.1128/CVI.00807-13
    1. Leroux-Roels I, Devaster JM, Leroux-Roels G, Verlant V, Henckaerts I, Moris P, et al. Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials. Vaccine. (2015) 33:577–84. 10.1016/j.vaccine.2013.10.052
    1. Fukuyama Y, Ikeda Y, Ohori J, Sugita G, Aso K, Fujihashi KK, et al. Molecular mucosal adjuvant to enhance immunity against pneumococcal infection in the elderly. Immune Netw. (2015) 15:9–15. 10.4110/in.2015.15.1.9
    1. Kataoka K, Fukuyama Y, Briles DE, Miyake T, Fujihashi K. Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae. Microbiol Immunol. (2017) 61:195–205. 10.1111/1348-0421.12487
    1. Moffitt K, Skoberne M, Howard A, Gavrilescu LC, Gierahn T, Munzer S, et al. Toll-like receptor 2-dependent protection against pneumococcal carriage by immunization with lipidated pneumococcal proteins. Infect Immun. (2014) 82:2079–86. 10.1128/IAI.01632-13
    1. Vecchi S, Bufali S, Uno T, Wu T, Arcidiacono L, Filippini S, et al. Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model. Eur J Pharm Biopharm. (2014) 87:310–7. 10.1016/j.ejpb.2014.01.002
    1. Heyward WL, Kyle M, Blumenau J, Davis M, Reisinger K, Kabongo ML, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age. Vaccine. (2013) 31:5300–5. 10.1016/j.vaccine.2013.05.068
    1. Jackson S, Lentino J, Kopp J, Murray L, Ellison W, Rhee M, et al. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. Vaccine. (2018) 36:668–74. 10.1016/j.vaccine.2017.12.038
    1. Koutsakos M, Illing PT, Nguyen THO, Mifsud NA, Crawford JC, Rizzetto S, et al. Human CD8 + T cell cross-reactivity across influenza A. B and C viruses. Nat Immunol. (2019) 20:613–25. 10.1038/s41590-019-0320-6
    1. Altenburg AF, Rimmelzwaan GF, de Vries RD. Virus-specific T cells as correlate of (cross-)protective immunity against influenza. Vaccine. (2015) 33:500–6. 10.1016/j.vaccine.2014.11.054
    1. Wilkinson TM, Li CKF, Chui CSC, Huang AKY, Perkins M, Liebner JC, et al. Preexisting influenza-specific CD4 + T cells correlate with disease protection against influenza challenge in humans. Nat Med. (2012) 18:274–80. 10.1038/nm.2612
    1. Nelson SA, Sant AJ. Imprinting and editing of the human CD4 T cell response to influenza virus. Front Immunol. (2019) 10:932. 10.3389/fimmu.2019.00932
    1. de Vries RD, Rimmelzwaan GF. Viral vector-based influenza vaccines. Hum Vaccines Immunother. (2016) 12:2881–901. 10.1080/21645515.2016.1210729
    1. Goulart C, Rodriguez D, Kanno AI, Converso TR, Lu YJ, Malley R, et al. combination of recombinant mycobacterium bovis BCG strains expressing pneumococcal proteins induces cellular and humoral immune responses and protects against pneumococcal colonization and sepsis. Clin Vaccine Immunol. (2017) 24:e133–117. 10.1128/CVI.00133-17
    1. Wang S, Curtiss R. Development of Streptococcus pneumoniae vaccines using live vectors. Vaccines. (2014) 2:49–88. 10.3390/vaccines2010049
    1. Mubarak A, Ahmed MS, Upile N, Vaughan C, Xie C, Sharma R, et al. A dynamic relationship between mucosal T helper type 17 and regulatory T-cell populations in nasopharynx evolves with age and associates with the clearance of pneumococcal carriage in humans. Clin Microbiol Infect. (2016) 22:.e1–736. 10.1016/j.cmi.2016.05.017
    1. Wang Y, Jiang B, Guo Y, Li W, Tian Y, Sonnenberg GF, et al. Cross-protective mucosal immunity mediated by memory Th17 cells against Streptococcus pneumoniae lung infection. Mucosal Immunol. (2017) 10:250–9. 10.1038/mi.2016.41
    1. Kuipers K, Jong WSP, van der Gaast-de Jongh CE, Houben D, van Opzeeland F, Simonetti E, et al. Th17-mediated cross protection against pneumococcal carriage by vaccination with a variable antigen. Infect Immun. (2017) 85:e281–217. 10.1128/IAI.00281-17
    1. Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence: a systems-level overview of immune cell biology and strategies for improving vaccine responses. Exp Gerontol. (2019) 124:110632. 10.1016/j.exger.2019.110632
    1. Kim EC, Kim JR. Senotherapeutics: emerging strategy for healthy aging and age-related disease. BMB Rep. (2019) 52:47–55. 10.5483/BMBRep.2019.52.1.293
    1. Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. (2014) 6:268ra179. 10.1126/scitranslmed.3009892
    1. Delhalle S, Bode SFN, Balling R, Ollert M, He FQ. A roadmap towards personalized immunology. NPJ Syst Biol Appl. (2018) 4:9. 10.1038/s41540-017-0045-9
    1. Poland GA, Ovsyannikova IG, Kennedy RB. Personalized vaccinology: a review. Vaccine. (2018) 36:5350–7. 10.1016/j.vaccine.2017.07.062
    1. Cotugno N, Ruggiero A, Santilli V, Manno EC, Rocca S, Zicari S, et al. OMIC Technologies and vaccine development: From the identification of vulnerable individuals to the formulation of invulnerable vaccines. J Immunol Res. (2019) 2019:8732191. 10.1155/2019/8732191
    1. Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, Haining WN, et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol. (2011) 12:786–95. 10.1038/ni.2067
    1. Li S, Rouphael N, Duraisingham S, Romero-Steiner S, Presnell S, Davis C, et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol. (2014) 15:195–204. 10.1038/ni.2789
    1. Fourati S, Cristescu R, Loboda A, Talla A, Filali A, Railkar R, et al. Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination. Nat Commun. (2016) 7:10369. 10.1038/ncomms10369
    1. Weinberg A, Pang L, Johnson MJ, Caldas Y, Cho A, Tovar-Salazar A, et al. The effect of age on the immunogenicity of the live attenuated zoster vaccine is predicted by baseline regulatory T cells and varicella-zoster virus-specific T cell immunity. J Virol. (2019) 93:1–17. 10.1128/jvi.00305-19
    1. van der Heiden M, Berbers GAM, Fuentes S, van Zelm MC, Boots AMH, Buisman AM. An explorative biomarker study for vaccine responsiveness after a primary meningococcal vaccination in middle-aged adults. Front Immunol. (2018) 8:1962. 10.3389/fimmu.2017.01962
    1. Mazur NI, Higgins D, Nunes MC, Melero JA, Langedijk AC, Horsley N, et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. (2018) 18:e295–311. 10.1016/S1473-3099(18)30292-5
    1. McIntosh EDG. Healthcare-associated infections: potential for prevention through vaccination. Ther Adv Vaccines Immunother. (2018) 6:19–27. 10.1177/2515135518763183
    1. Wan Tso GH, Reales-Calderon JA, Pavelka N. The elusive anti-candida vaccine: lessons from the past and opportunities for the future. Front Immunol. (2018) 9:897. 10.3389/fimmu.2018.00897
    1. Frenck RW, Ervin J, Chu L, Abbanat D, Spiessens B, Go O, et al. Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial. Lancet Infect Dis. (2019) 19:631–40. 10.1016/S1473-3099(18)30803-X
    1. Hainz U, Aigner K, Asch E, Berger P, Böhmer F, Feldkircher B, et al. Impfschutz im alter?: sind österreichische senioren durch Impfungen ausreichend geschützt?? Wiener Medizinische Wochenschrift. (2002) 114:187–93.
    1. Hsu JP, Zhao X, Chen MIC, Cook AR, Lee V, Lim WY, et al. Rate of decline of antibody titers to pandemic influenza A (H1N1-2009) by hemagglutination inhibition and virus microneutralization assays in a cohort of seroconverting adults in Singapore. BMC Infect Dis. (2014) 14:414. 10.1186/1471-2334-14-414
    1. Weinberger B. Vaccines for the elderly: current use and future challenges. Immun Ageing. (2018) 15:3. 10.1186/s12979-017-0107-2
    1. Shedrawy J, Henriksson M, Hergens MP, Askling HH. Estimating costs and health outcomes of publicly funded tick-born encephalitis vaccination: a cost-effectiveness analysis. Vaccine. (2018) 36:7659–65. 10.1016/j.vaccine.2018.10.086
    1. Weinberger B, Keller M, Fischer KH, Stiasny K, Neuner C, Heinz FX, et al. Decreased antibody titers and booster responses in tick-borne encephalitis vaccinees aged 50-90 years. Vaccine. (2010) 28:3511–5. 10.1016/j.vaccine.2010.03.024

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel